Norwegian ‘Oslo Patient’ Achieves Rare HIV Remission Following Sibling Stem Cell Transplant
A 63-year-old Norwegian man, now referred to as the “Oslo patient,” has entered long-term remission from HIV, marking a rare medical milestone. The breakthrough occurred after the patient received a stem cell transplant from his brother, a procedure that effectively remodeled his entire immune system.
According to a study published Monday, April 13, 2026, in the journal Nature Microbiology, the patient is “likely cured” of the virus. This case adds to a incredibly small group of individuals who have achieved similar results following bone marrow transplants, though the Oslo patient’s case is distinct because the donor was a sibling rather than an unrelated individual.
The Role of a Rare Genetic Mutation
The success of the transplant was driven by a rare genetic mutation carried by the patient’s brother. The sibling possesses two copies of the CCR5 delta 32 mutation, which disables a specific protein on the surface of immune cells. Because HIV typically exploits this protein to infect cells, the mutation effectively locks the virus out of its primary targets.
Medical experts noted the extreme rarity of this occurrence. In northern European populations, the frequency of the CCR5Δ32/Δ32 mutation is approximately 1%, and there is only a 25% probability that a sibling will be a compatible match for a transplant.
From Cancer Treatment to Viral Remission
The allogeneic hematopoietic stem cell transplantation (HSCT) was originally performed when the patient was 58 years old to treat a rare form of blood cancer. Researchers from Oslo University Hospital closely monitored the process after discovering the brother’s genetic resistance to HIV just before the operation.
The medical team tracked “chimerism” to determine the extent to which the donor’s immune cells had replaced the patient’s own. The results were definitive: four years after the transplant, all traces of functioning HIV DNA had been cleared from the patient’s system.
The patient was able to cease his HIV medication two years after the procedure. As of five years post-HSCT, there has been no evidence of viral rebound. This outcome is particularly significant because although current medications can control HIV and stop it from replicating, they cannot completely eradicate the virus from the body.
Implications for Future Research
Researchers stated that the case of the Oslo patient provides “valuable evidence to the existing knowledge base regarding HIV cure cases.” By studying these rare instances of remission, scientists can better understand HIV pathology, molecular mechanisms, and predictive biomarkers.
These findings are critical for the broader scientific community as they perform toward developing a full cure for HIV, offering insights that may extend beyond patients who undergo stem cell transplants for cancer treatment.
